Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sjogrens Clear all
Active, not recruiting Phase 3 Interventional

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969
View directory record Official record
Conditions
Sjogrens Syndrome
Interventions
Nipocalimab, Placebo, Standard of care treatment
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
43
States / cities
Chula Vista, California • Fullerton, California • La Palma, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 4:29 AM EDT
Recruiting No phase listed Observational

The Pathogenesis and Natural History of Sjogren's Disease

NCT01425892
View directory record Official record
Conditions
Sjogren's Syndrome, Salivary Gland, Pathogenesis
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
16 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease

NCT04391894
View directory record Official record
Conditions
Dry Eye
Interventions
ECF843, ECF843 vehicle
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
52
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 21, 2026, 4:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Differential Diagnosis of Sjögren's Versus Non-Sjögren's Dry Eye

NCT04493658
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye Syndromes, Ocular Surface Disease, Sjogren's Syndrome
Interventions
Questionnaires, Tear fluid sampling, Impression Cytology
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 21, 2026, 4:29 AM EDT
Completed No phase listed Observational

Patient-Centered Assessment of Symptoms and Outcomes

NCT03952624
View directory record Official record
Conditions
Fatigue, Cancer, CFS, ME/CFS, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Lupus, Systemic Lupus Erthematosus, Sjogrens
Interventions
Not listed
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome

NCT02915159
View directory record Official record
Conditions
Sjogrens Disease
Interventions
Abatacept, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
19
States / cities
Fullerton, California • Riverside, California • Lakewood, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 21, 2026, 4:29 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Quest to Analyze One Thousand Humans Meditating

NCT06583395
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
Interventions
Advanced multi-component meditation practice
Behavioral
Lead sponsor
Tobias Moeller-Bertram
Industry
Eligibility
21 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Palm Desert, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 21, 2026, 4:29 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Sjogrens Syndrome Measured by Ultrasound

NCT03411850
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Orencia, Placebo
Biological · Other
Lead sponsor
Arthritis & Rheumatism Associates, P.C.
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

TrueTear in Sjogren's Disease Patients

NCT03719885
View directory record Official record
Conditions
Dry Eye Syndromes, Sjogren's Syndrome
Interventions
TrueTear Intranasal Tear Neurostimulator
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
22 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 21, 2026, 4:29 AM EDT
Active, not recruiting Phase 3 Interventional

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT05985915
View directory record Official record
Conditions
Sjogrens Syndrome
Interventions
Ianalumab (VAY736), Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
32
States / cities
Fullerton, California • La Palma, California • Van Nuys, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 4:29 AM EDT
Recruiting Phase 2 Interventional

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

NCT06991114
View directory record Official record
Conditions
Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease
Interventions
Allogeneic NK Cells
Drug
Lead sponsor
Artiva Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
31
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 4:29 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye

NCT06364657
View directory record Official record
Conditions
Sjogren's Syndrome, Dry Eye, Neurotrophic Keratitis
Interventions
Eye Exam
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 21, 2026, 4:29 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

NCT06684847
View directory record Official record
Conditions
Primary Sjogrens Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
42
States / cities
Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 1 Interventional

Fecal Microbial Transplant (FMT) for Sjogrens Syndrome

NCT03926286
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
FMP-30
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2020 · Synced Oct 21, 2026, 4:29 AM EDT